InCube Labs' team has expertise across a range of disciplines: pharmacology and physiology, protein and polymer chemistry, tissue engineering, mechanical engineering and material science, electronics and software, industrial design, clinical development and manufacturing. Our leadership has deep experience in commercializing innovations and company building.
- Mir Imran, Chairman & CEO
Mir Imran founded InCube Labs to focus on his passion: creating medical solutions that change the standard of care in critical healthcare markets. After attending medical school, Mir began his career as a healthcare entrepreneur in the late 1970's and has founded numerous game-changing companies since those early days. Over the decades, he has become one of the leading inventors and entrepreneurs in the field. Mir now holds more than 200 issued patents and is perhaps most well known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator. As an entrepreneur, Mir has founded more than 20 life sciences companies; 15 of his companies have seen "liquidity events" (IPO/Acquisition). Mir's expertise spans a wide range of clinical areas from interventional cardiology to chronic pain, obesity and CNS disorders. Mir actively collaborates with the nation's top universities on research and development including Stanford, Rutgers, Johns Hopkins, UTSW, etc. Mir also founded InCube Ventures, a life sciences venture fund, where he has led investments in a range of promising ventures. Mir sits on Boards of several life sciences companies. He holds an M.S. in bioengineering and a B.S. in electrical engineering from Rutgers. He also attended CMDNJ/Rutgers Medical School.
- Mir Hashim, Vice President, Research & Development
Mir Hashim brings more than 20 years of pharmaceutical research and development experience to InCube Labs, including leadership and management of a multi-laboratory, multi-group, pharmacology section. His breadth of knowledge and experience in pharmacology and physiology spans a variety of therapeutic areas including CNS, cardiovascular, gastrointestinal, anesthesia, and metabolic diseases such as diabetes and obesity. Prior to InCube, Mir spent 18 years at Glaxo Smith Kline where he most recently served as the head of Pharmacology. Mir has deep experience in drug discovery and development, international regulatory submissions, international product development, as well as in-licensing and out-licensing of drug candidates. Mir holds a B.S. in Biology and Chemistry from Osmania University, India; an M.S. in Biology from Central University of Hyderabad, India, as well as a PhD in Medicine/Pharmacology from Memorial University, St. John's, Canada.
- Ben Tranchina, Vice President, Engineering
Ben brings more than 20 years of experience in engineering, innovation and leading product development teams in both start-ups and large multi-national corporations. Ben joined InCube Labs from St. Jude Medical’s Neuromodulation Division where he most recently served as Vice President of Product Development leading research, technical innovations, engineering, program management and the life cycle of product development for the entire product range. Prior to joining St. Jude Medical he was a principal in several entrepreneurial ventures spanning the medical, semiconductor, integrated circuit design and radio astronomy industries. Earlier in his career, he proudly served in the U.S. Navy. Ben is a recognized innovator with several patents and awards, including NMD’s Inventor of the Year. Ben holds a B.S. and M.S. in Electrical Engineering from the University of Texas at Dallas.
- Phil Morgan, Vice President, ICL Texas
Phil Morgan brings more than 20 years of pharmaceutical research and development experience to Incube Labs and has extensive experience in drug development and the regulatory approval process. He was the pre-clinical pharmacology expert for several drugs including Wellbutrin SR and Zyban. Prior to joining Incube Labs, Phil co-founded several successful life science companies and served as the president and CEO of Cytospect, Cytoscan and Neurotherapeutics. Before that, he was the Head of the Department of Molecular Pharmacology and a Senior Scientist at GlaxoSmithKline and a Visiting Fellow and Scientist at the National Institutes of Health, Bethesda, MD. Phil has published over 50 peer-reviewed articles and holds a PhD from London University and an MBA from Duke University.
- Stephanie McGrory, Vice President, Business Development & Marketing
Stephanie brings 20 years of marketing, communications and business management experience. In her role at InCube, Stephanie is responsible for building and managing relationships for strategic partnerships and collaborations across industry and academia, for the Lab and its portfolio companies. Stephanie also manages communications and marketing programs for InCube and InCube companies. Prior to joining InCube, Stephanie was a founder and Executive Vice President for Greenough Communications, a nationally-recognized marketing services firm specializing in marketing programs and public relations for technology and consumer-products companies. There she managed client service operations, new business and staff development.
- Syed Zaidi, Vice President, Finance & Operations
Syed is an industry veteran with more than 25 years of experience in accounting, HR and operations. In his role at InCube, Syed has been instrumental in launching and running operations for more than a dozen start-ups in the last 15 years. Syed received his MBA from Osmania University in Hyderabad, India.
- Mike Billig, Vice President, Regulatory, Quality & Clinical
Mike serves as Vice President, Regulatory, Quality & Clinical. In addition to his work with InCube, Mike is CEO of Experien Group, a clinical and regulatory consulting firm, which he co-founded in 2003. His entire 35+ year professional career has been involved with regulatory affairs, quality systems, clinical research, and general management for medical device companies. Mike has secured regulatory approval for hundreds of medical device products across the U.S., Europe, Canada, Central and South America, and Asia. He has been involved with a variety of product areas, including sterile disposable products, electronic instruments, robotics, combination products, and devices for regenerative medicine. Mike has particular expertise in the interventional cardiology and cardiac surgery areas.
Mike entered the device industry in 1973 at Medtronic, setting up the company’s first microbiology laboratory in Minneapolis. He transitioned to regulatory affairs at Medtronic as a Project Regulatory Manager at the time that the U.S. Medical Device Amendments of 1976 were finalized. Mike went on to work for a number of other large companies and public corporations, including Syntex, Oximetrix, Abbott and Guidant. Mike spent the majority of his time in the industry in senior management for start-ups, holding executive-level positions for 20 years at companies such as CardioThoracic Systems, Cardiometrics, Converge Medical, and Timi3 Systems. In these early stage companies, Mike oversaw the regulatory, clinical and quality teams and provided strategic direction for product development and marketing. As a vice president of several companies and the former President and CEO of Timi3 Systems, Mike provided overall leadership for strategic business affairs and company growth. He was instrumental with substantial fundraising, multiple successful IPOs, and company sales/corporate acquisitions from both seller and buyer positions.
Mike earned his BS degree in Microbiology from the University of Minnesota.
- Joel Harris, Senior Director of Intellectual Property
Joel brings more than 20 years of experience in the medical device industry including 12 years of IP experience developing and managing patent portfolios for emerging medical device companies. Joel has worked for Wilson Sonsini Goodrich & Rosati PC, Townsend and Townsend and Crew LLP and Rita Medical Systems Inc. Joel has also held engineering and management positions at divisions of Guidant, Abbott Laboratories and Johnson and Johnson. Joel is admitted to practice before the United States Patent and Trademark Office. He is a graduate of Santa Clara Law School and a recipient of an Emery Scholarship for Academic Achievement and Witkin and Cali Awards for Academic Excellence (Golden Gate University). In addition to his law degree, Joel holds a B.S. Degree in Chemical Engineering from Northwestern University and an M.S. Degree in Bioengineering from Penn State University.
- Andrew Mangogna, Director, Software
Andrew has over 30 years of software development experience in applications ranging from laboratory instruments to video special effects and high speed data recording. For the last 10 years he has worked specifically in software for medical devices. Andrew's abiding interest has always been the application of formal methods of engineering to the production of high quality software, in particular the translation of formal analytical models of software logic into executable programs. Andrew is a contributor to several open source software projects and holds a B.S. in Chemistry from Louisiana State University.